BIEFFE MEDITAL SPA

Spectral Medical filed a preliminary base shelf prospectus allowing up to $100 million in securities offerings over 25 months to maintain financial flexibility ahead of upcoming milestones.

Simtra BioPharma Solutions has completed construction of a new 1,800 square meter production facility at its Halle, Germany campus, expanding total production area to nearly 12,000 square meters.

• Basil Systems has raised $11.5 million in funding led by Golden Ventures, with participation from Hearst Ventures and Argosy Capital, to expand its AI-powered product lifecycle intelligence platform. • The company has built BasilLink, the largest indexed dataset in life sciences with over 600 million records, providing real-time insights for regulatory submissions, clinical planning, and post-market surveillance. • Already utilized by four of the five largest global medical device companies and in trials with major pharmaceutical firms, Basil's platform aims to transform fragmented regulatory and clinical data into actionable intelligence.

Drug shortages in the US reached 323 active cases in early 2024, with 48% of shortages persisting since 2022, affecting critical medications including chemotherapies, antimicrobials, and IV fluids.

The brain hemorrhage treatment market is projected to experience substantial growth through 2032, driven by an aging population and increasing prevalence of risk factors such as hypertension and traumatic brain injuries.

Spectral Medical's Tigris trial, evaluating Polymyxin B Hemoperfusion (PMX) for endotoxemia and septic shock, has enrolled 146 patients, showing strong progress.

The Duchossois Family Institute (DFI) at UChicago is set to begin clinical trials in January to investigate rebuilding the gut microbiome in compromised patients.

Spectral Medical faces enrollment delays in its pivotal Tigris trial for Toraymyxin due to supply chain disruptions exacerbated by Hurricane Helene.

Spectral Medical's Tigris trial, evaluating PMX for endotoxemia and septic shock, has enrolled 136 patients as of November 2024.

US drug shortages have decreased from a peak of 323 to 277 as of September 2024, though 50% of these shortages have persisted for two or more years, significantly impacting essential medications.